With the knowledge that the treatment landscape for breast cancer is changing rapidly [41], it will be of important clinical significance to use such integrative analyses to distinguish between resistant tumors primarily driven by ERBB2 aberrations and those driven by downstream pathways. This evidence concerns the gene ERBB2 and breast cancer.